Photostimulation device for neurodegenerative disease treatment

WO2026235103A1PCT designated stage Publication Date: 2026-11-12NARA INSTITUTE OF SCIENCE AND TECHNOLOGY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/JP2026/017238
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-09
Filing Date
2026-04-30
Publication Date
2026-11-12

Smart Images

  • Figure JP2026017238_12112026_PF_FP_ABST
    Figure JP2026017238_12112026_PF_FP_ABST
Patent Text Reader

Abstract

A photostimulation device for neurodegenerative disease treatment comprising: a support body 11; a first light source 21 that is supported by the support body on a parallel surface parallel to a longitudinal direction of the support body, and that emits stimulation light in a direction perpendicular to the longitudinal direction; and an image sensor 23 that is supported by the support body on the parallel surface, and that receives light incident from the direction perpendicular to the longitudinal direction.
Need to check novelty before this filing date? Find Prior Art

Description

Photostimulation device for treating neurodegenerative diseases

[0001] The present disclosure relates to a photostimulation device for treating neurodegenerative diseases.

[0002] With the aging of the population, the number of patients suffering from Parkinson's disease is also increasing. However, at present, it is difficult to permanently cure Parkinson's disease, and treatment is mainly performed by palliative therapy.

[0003] As one of the palliative therapies, deep brain stimulation therapy is known. According to this treatment method, a stimulation electrode is inserted into the deep part of the brain, and an electrical signal is sent to the stimulation electrode from a stimulation device connected to the stimulation electrode via a cable and implanted in the body, thereby applying electrical stimulation to the deep part of the brain to suppress symptoms such as tremors. For example, Patent Document 1 discloses a device for guiding a stimulation electrode to an appropriate position.

[0004] Japanese Patent Publication No. 2024-535859

[0005] As described above, according to the current treatment methods, since the symptoms specific to Parkinson's disease are only suppressed when the device is turned on, research and development of new treatments and treatment methods capable of permanently treating Parkinson's disease are desired. In addition, similar to Parkinson's disease, research and development of treatments and treatment methods for cerebral neurological diseases, such as changes in the secretion of substances in the brain, changes in nerve cells (neurons) in the brain, and abnormal electrical activity, are desired.

[0006] An object of the present disclosure is to provide a photostimulation device for treating neurodegenerative diseases that can be used for the research and development of new treatments and treatment methods for cerebral neurological diseases including Parkinson's disease.

[0007] A photostimulation device for treating neurodegenerative diseases according to an embodiment of the present disclosure includes a support, a first light source supported by the support on a parallel plane parallel to the longitudinal direction of the support and configured to emit stimulation light in a direction perpendicular to the longitudinal direction, and an image sensor supported by the support on the parallel plane and configured to receive light incident from a direction perpendicular to the longitudinal direction.

[0008] According to one embodiment of the present disclosure, a photostimulation device for the treatment of neurodegenerative diseases is provided, which can be used in the research and development of new treatment methods for neurological diseases.

[0009] Figure 1 shows the structure of the first embodiment of the photostimulation device for the treatment of neurodegenerative diseases, where (a), (b), and (c) are a side view, a top view, and a front view of the photostimulation device for the treatment of neurodegenerative diseases, respectively. Figure 2 is a block diagram showing the configuration of the first embodiment of the photostimulation device for the treatment of neurodegenerative diseases. Figure 3 is a schematic diagram illustrating a method for treating neurodegenerative diseases. Figure 4 is a flowchart illustrating a method for operating the photostimulation device for the treatment of neurodegenerative diseases. Figure 5 is a schematic diagram showing the positional relationship between the photostimulation device for the treatment of neurodegenerative diseases inserted into the brain and a group of target neurons, where (a) shows the state in which stimulating light is being irradiated and (b) shows the state in which excitation light is being irradiated. Figure 6 shows the structure of the second embodiment of the photostimulation device for the treatment of neurodegenerative diseases, where (a), (b), and (c) are a side view, a top view, and a front view of the photostimulation device for the treatment of neurodegenerative diseases, respectively. Figure 7 shows the structure of a photostimulation device for the treatment of neurodegenerative diseases according to the third embodiment, where (a), (b), and (c) are a side view, a top view, and a front view of the photostimulation device for the treatment of neurodegenerative diseases, respectively. Figure 8 is a block diagram showing the configuration of a photostimulation device for the treatment of neurodegenerative diseases according to the third embodiment.

[0010] Optogenetics is being explored as a new treatment method for neurological diseases. Optogenetics is a technique that uses light to control nerve cells by introducing light-sensitive proteins, which are activated by light, into nerve cells using genetic methods.

[0011] Traditionally, techniques for manipulating nerve cells have included electrical stimulation and drug administration. However, because biological tissues are conductors, it is difficult to deliver electrical stimulation only to specific cells, resulting in non-specific stimulation of axons and cell bodies around the electrodes. Furthermore, it can be difficult to distinguish whether electrical stimulation is enhancing or inhibiting nerve cells. These factors make it challenging to identify the correlation between behavioral responses induced by electrical stimulation and the nerve cells responsible for those responses. Additionally, many drugs circulate throughout the body and do not specifically act on nerve cells.

[0012] In these respects, optogenetics can be applied to express and specifically activate photosensitive proteins in specific cells. Furthermore, photoion channels and photoion pumps, which are used as photosensitive proteins, generally have a rapid response. When stimulated by light, ions move, changing the electrical potential of the nerve cell to which the photosensitive protein has been introduced, thereby enhancing or suppressing the nerve cell. Therefore, by introducing such photosensitive proteins into specific nerve cells, it is possible to manipulate the nerve cells specifically and with a rapid response rate using stimulated light.

[0013] Thus, if it becomes possible to selectively irradiate specific locations or nerve cells within the brain with stimulating light and manipulate nerve cells, it would be possible to study in detail the function of nerve cells in the brain and the dysfunction caused by disease, and it would also be possible to induce plasticity in nerve cells.

[0014] Therefore, research and development of new treatment methods for neurological diseases using optogenetics is expected. This disclosure aims to provide a light stimulation device for the treatment of neurodegenerative diseases that is suitable for new treatments for neurological diseases using optogenetics, as well as for research for such treatments.

[0015] The embodiments of this disclosure will be described below with reference to the drawings. This disclosure is not limited to the embodiments described below, and design modifications can be made as appropriate within the scope of satisfying the configuration of this disclosure. In the following description, the same reference numerals will be used in common across different drawings for the same parts or parts having similar functions, and repeated descriptions may be omitted. In addition, the configurations described in the embodiments and modifications may be combined or modified as appropriate without departing from the gist of this disclosure. In order to make the explanation easier to understand, the configurations in the drawings referenced below may be simplified or schematic, or some components may be omitted. Also, the dimensional ratios between components shown in each figure do not necessarily represent the actual dimensional ratios.

[0016] (First Embodiment) Figure 1 is a diagram showing the structure of the optical stimulation device 51 for the treatment of neurodegenerative diseases according to this embodiment, and Figure 2 is a block diagram showing the configuration of the optical stimulation device 101 for the treatment of neurodegenerative diseases according to this embodiment. In Figure 1, (a), (b), and (c) are a side view, a top view, and a front view of the optical stimulation device 51 for the treatment of neurodegenerative diseases, respectively.

[0017] As shown in Figure 1, the optical stimulation device 51 for the treatment of neurodegenerative diseases comprises a support 11, a first light source 21, a second light source 22, and an image sensor 23.

[0018] The support 11 has a shape that extends in the longitudinal direction (x direction). In this embodiment, the support 11 has, for example, a needle tube shape and has a cylindrical space 11c along the longitudinal direction. The tip 11t of the support 11 is cut off at an angle and is pointed. The support 11 is made of SUS, for example, an injection needle. The support 11 may be made of a material other than metal such as SUS, for example, resin.

[0019] Furthermore, a notch (half-cut) is formed along the longitudinal direction for a predetermined length from the tip portion 11t, creating a recess 11d. The bottom surface 11u of the recess 11d is parallel to the longitudinal direction.

[0020] The first light source 21, the second light source 22, and the image sensor 23 are supported by the support 11 in a plane parallel to the longitudinal direction of the support 11. In this embodiment, the first light source 21, the second light source 22, and the image sensor 23 are located within the recess 11d and supported by the bottom surface 11u.

[0021] In this embodiment, the optical stimulation device 51 for the treatment of neurodegenerative diseases further comprises a substrate 12. The substrate 12 is, for example, a flexible substrate and includes a main section 12m on which a first light source 21, a second light source 22, and an image sensor 23 are mounted, and a wiring section 12w that makes electrical connections between these elements mounted on the main section 12m and the outside. The main section 12m is supported on a bottom surface 11u, and the wiring section 12w is located in a cylindrical space 11c.

[0022] The substrate 12 may be a non-flexible substrate. In this case, the substrate 12 is located in the recess 11d, and wiring is arranged in the cylindrical space 11c to make an electrical connection between the substrate 12 and the outside. The wiring may be a flexible substrate or a conductive fine wire with an insulating coating on the outside. Alternatively, a wireless module capable of communicating with the outside and a small battery may be placed on the substrate 12, and communication with the outside may be performed by wireless communication.

[0023] As will be detailed below, the first light source 21 is driven during the repair of the target neuron group and emits stimulating light toward the target neuron group. The wavelength of the stimulating light is preferably the wavelength to which the light-driven ion channels introduced into the target neuron group respond. For example, the wavelength of the stimulating light is in the visible light band, more specifically, in the blue to yellow band (e.g., about 430 nm to about 590 nm). Alternatively, it may be in the red band (e.g., about 590 nm to about 770 nm).

[0024] Meanwhile, the second light source 22 is activated during observation of the target neuron group and emits excitation light. The excitation light has a wavelength that causes the fluorescent protein introduced into the target neuron group, or the fluorescent probe that interacts with the target neuron group, to emit fluorescence. The wavelength of the excitation light is shorter than the wavelength of fluorescence, for example, a wavelength in the ultraviolet to green light band.

[0025] Preferably, the wavelength of the excitation light from the second light source 22 and the wavelength of the stimulating light from the first light source 21 are different from each other. By having different wavelengths, the excitation light is suppressed from affecting the repair of target neurons. The size of the first light source 21 and the second light source 22 is, for example, several tens of micrometers × several tens of micrometers or more and 300 micrometers × 300 micrometers or less, and the size of the emission surfaces of the stimulating light and excitation light are also of a similar size.

[0026] However, if the stimulating light emitted from the first light source 21 can also excite fluorescent proteins or fluorescent probes and cause them to emit fluorescence, and if the intensity of the stimulating light that causes fluorescence does not substantially affect the repair of the target neuron group, then the photostimulation device 51 for the treatment of neurodegenerative diseases does not need to be equipped with a second light source 22. In this case, the fluorescent proteins or fluorescent probes are excited using stimulating light of a lower intensity than the stimulating light used to repair the target neuron group.

[0027] The image sensor 23 detects fluorescence emitted from the target neuron group and generates a fluorescence image. The image sensor 23 is, for example, a CMOS image sensor or a CCD image sensor. There are no particular restrictions on the pixel count size of the image sensor 23, and it can be appropriately selected depending on the size of the target neuron group being studied, the distribution range of the target neuron group, and the purpose of the research or treatment. For example, the size of the image sensor 23 is approximately tens of micrometers x tens of micrometers or larger, and several hundred micrometers x several hundred micrometers or smaller, and the number of pixels is approximately tens of pixels x tens of pixels or larger, and several hundred to several thousand pixels or smaller. The frame rate is, for example, several frames / second to several hundred frames / second.

[0028] If the excitation light emitted from the second light source 22 (described later) directly enters the image sensor 23 and may affect the acquisition of the fluorescence image, an optical filter that blocks the excitation light may be provided on the light-receiving surface of the image sensor 23.

[0029] The first light source 21, the second light source 22, and the image sensor 23 are preferably bare chips in terms of their small external size. The first light source 21 and the second light source 22 are LED chips, and the image sensor 23 is a CMOS image sensor chip. The first light source 21 and the second light source 22 may also be laser diode chips. These chips are mounted on the substrate 12 by solder, epoxy resin, adhesive, etc. By having the first light source 21, the second light source 22, and the image sensor 23 as bare chips, the volume of each can be reduced, the overall volume of the device can be reduced, and the invasive effects when the optical stimulation device 51 for the treatment of neurodegenerative diseases is inserted into the brain can be reduced.

[0030] Preferably, the first light source 21, the second light source 22, and the image sensor 23 are arranged in a direction parallel to the longitudinal direction in the main portion 12m of the substrate 12. This reduces the cross-sectional area of ​​the optical stimulation device 51 for the treatment of neurodegenerative diseases in the direction perpendicular to the longitudinal direction, further reducing the invasive effects when the optical stimulation device 51 for the treatment of neurodegenerative diseases is inserted into the brain. Furthermore, it is preferable that the image sensor 23 is located between the first light source 21 and the second light source 22. This reduces the distance between the image sensor 23 and the first light source 21, and the distance between the image sensor 23 and the second light source 22, respectively, allowing for efficient observation of the target neuron group repaired by the stimulating light.

[0031] Furthermore, because the first light source 21, the second light source 22, and the image sensor 23 are mounted on a substrate 12 supported on the bottom surface 11u of the recess 11d, the first light source 21 and the second light source 22 can emit stimulating light and excitation light in a direction perpendicular to the longitudinal direction. The image sensor 23 can also receive fluorescence incident from a direction perpendicular to the longitudinal direction. Therefore, compared to the case where the first light source 21 is placed on the end face of the support 11 and stimulating light is emitted from the end face of the support 11, the emission surface of the first light source 21 can be made larger, and a wider group of target neurons can be irradiated with stimulating light. In addition, the activation state of the nerve cell group can be detected by the image sensor using fluorescence or the like. Thus, the effect of treatment with stimulating light can be confirmed.

[0032] The optical stimulation device 51 for the treatment of neurodegenerative diseases further comprises a transparent protective layer 31 covering the first light source 21, the second light source 22, and the image sensor 23. The transparent protective layer 31 protects the first light source 21, the second light source 22, and the image sensor 23 from the external environment. The transparent protective layer 31 is transparent to stimulation light, excitation light, and fluorescence. Here, transparent means having a transmittance of 90% or more at the central wavelength of each of the stimulation light, excitation light, and fluorescence. The transparent protective layer 31 is composed of a transparent and biocompatible polymer film, such as parylene C.

[0033] The transparent protective layer 31 may contain a diffusing material or have a lens-based diffusion structure formed on its surface in the upper portion of the emission surface 21a of the first light source 21 and the upper portion of the emission surface 22a of the second light source 21, so that stimulating and excitation light can be emitted over a wide area. On the other hand, in the region above the light-receiving surface 23a of the image sensor 23, it is preferable that the aforementioned diffusion structure is not formed on the transparent protective layer 31 so that a clear image can be obtained by fluorescence.

[0034] Next, the size of the photostimulation device 51 for the treatment of neurodegenerative diseases will be described. Since the photostimulation device 51 for the treatment of neurodegenerative diseases is inserted into the brain, a smaller volume of the photostimulation device 51 will reduce the invasiveness when inserted into the brain. For example, the length of the support 11 in the longitudinal direction is several centimeters to about 10 centimeters, and the outer diameter is several hundred micrometers to about 2 mm. Also, the diameter of the cylindrical space 11c (i.e., the inner diameter of the support 11) is several tens of micrometers to several hundred micrometers. In addition, the length of the bottom surface 11u in the longitudinal direction is several centimeters or less.

[0035] The photostimulation device 51 for the treatment of neurodegenerative diseases is used for a procedure lasting several hours and is removed from the brain after the procedure is completed. The time that the photostimulation device 51 is in contact with biological tissue is also only several hours, but from the viewpoint of reducing the impact on biological tissue, it is preferable that the outer surface of the photostimulation device 51 for the treatment of neurodegenerative diseases is made of a biocompatible material. For example, SUS (stainless steel) which makes up the support 11 and parylene C which makes up the transparent protective layer 31 have excellent biocompatibility.

[0036] Next, the optical stimulation device 101 for the treatment of neurodegenerative diseases will be described with reference to Figure 2. The optical stimulation device 101 for the treatment of neurodegenerative diseases comprises the optical stimulation device 51 for the treatment of neurodegenerative diseases described above and a control device 60 for controlling the optical stimulation device 51 for the treatment of neurodegenerative diseases. The control device 60 includes a first light source drive circuit 61, a second light source drive circuit 62, a signal processing circuit 63, a control circuit 65, an input device 66, and a display 67.

[0037] The first light source drive circuit 61 drives the first light source 21 based on a control signal from the control circuit 65. Specifically, the first light source drive circuit 61 drives the first light source 21 by pulse drive or DC drive. When pulse drive is performed, it is preferable to light up the first light source 21 at a frequency suitable for repairing the target neuron group. For example, the pulse drive frequency is approximately 10 Hz to 200 Hz. The first light source drive circuit 61 also controls the intensity of the stimulating light emitted from the first light source 21. When pulse drive is performed, the intensity of the stimulating light can be controlled by the duty cycle. When DC drive is performed, the intensity of the stimulating light can be controlled by the drive current value.

[0038] The second light source drive circuit drives the second light source 22 based on a control signal from the control circuit 65. The second light source drive circuit 62 also drives the second light source 22 by pulse drive or DC drive. When pulse drive is performed, it is preferable to light up the second light source 22 at a frequency suitable for observing the target neuron group. For example, the pulse drive frequency is approximately 10 Hz to 200 Hz. The second light source drive circuit 62 controls the intensity of the excitation light emitted from the second light source 22. When pulse drive is performed, the intensity of the excitation light can be controlled by the duty cycle. When DC drive is performed, the intensity of the excitation light can be controlled by the drive current value.

[0039] The signal processing circuit 63 commands the image sensor 23 to start imaging based on the control signal from the control circuit 65. The signal processing circuit 63 also receives a fluorescence detection signal from the image sensor 23 and outputs an image signal to the control circuit 65.

[0040] The control circuit 65, for example, is composed of a microcontroller and controls the first light source drive circuit 61, the second light source drive circuit 62, and the signal processing circuit 63 based on input from the operator received via the input device 66. It also displays the image signal received from the signal processing circuit 63 on the display 67.

[0041] Next, we will describe the operation method of the optical stimulation device for treating neurodegenerative diseases, the control method of the optical stimulation device for treating neurodegenerative diseases, and the treatment method for neurodegenerative diseases according to this embodiment.

[0042] FIG. 3 is a schematic diagram illustrating a method for treating a neurodegenerative disease, and FIG. 4 is a flowchart illustrating an operation method of a photostimulation device for treating a neurodegenerative disease. Further, FIG. 5 is a schematic diagram showing the positional relationship between the photostimulation device 51 for treating a neurodegenerative disease inserted into the brain 201 and the target neuron group 202, wherein (a) shows a state in which stimulation light 203 is irradiated, and (b) shows a state in which excitation light 204 is irradiated. As described above, the photostimulation device and the photostimulation apparatus for treating a neurodegenerative disease of the present disclosure utilize optogenetics.

[0043] (1) First, using optogenetics, an adeno-associated viral vector (AAV) is introduced into the target neuron group to express light-activated photo-ion channels (STEP 1 to STEP 3). Known gene manipulation techniques can be used for this process.

[0044] Specifically, a promoter gene for expressing photo-ion channels in the target neuron group is prepared (STEP 1). The promoter gene may be of one type or a plurality of types. The target neuron group can be selected according to the disease to be treated, and a photo-ion channel which is a photosensitive protein suitable for the selected target neuron group can be selected. For example, the target neuron group includes dopamine neurons, glutaminergic neurons, GABA neurons and the like, and the photo-ion channels include ChR2, ChrimsonR and the like.

[0045] Next, an adeno-associated viral vector is prepared (STEP 2). For example, a commercially available adeno-associated virus is prepared, and the promoter gene is introduced thereto to produce the adeno-associated viral vector. When a plurality of types of promoter genes are introduced, adeno-associated viral vectors corresponding to the number of the promoter genes are produced.

[0046] Next, an adeno-associated virus vector is introduced into the brain to infect the target neuron group. As a result, light-gated ion channels and fluorescent proteins are expressed in the target neuron group (STEP 3). For example, the expression of light-gated ion channels and fluorescent proteins takes several weeks.

[0047] (2) A procedure is performed using the optical stimulation device for neurodegenerative disease treatment and the optical stimulation apparatus for neurodegenerative disease treatment (STEP 4 to STEP 5).

[0048] Specifically, first, as shown in FIG. 5(a), the optical stimulation device 51 for neurodegenerative disease treatment is inserted into the brain. More specifically, the optical stimulation device for neurodegenerative disease treatment is inserted into the brain 201 such that the parallel surface of the optical stimulation device 51 for neurodegenerative disease treatment faces the target neuron group 202 (STEP 4). After that, the optical stimulation apparatus 101 for neurodegenerative disease treatment is operated, and stimulation light 203 is emitted from the first light source 21 to the target neuron group 202.

[0049] Since the first light source 21 is supported on the surface parallel to the longitudinal direction of the optical stimulation device 51 for neurodegenerative disease treatment, the emission surface 21a of the first light source 21 can be made large. Therefore, the stimulation light can be applied to the target neuron group over a wide range.

[0050] Unlike electrical stimulation, the stimulation light 203 incident into the brain 201 can specifically stimulate the target neuron group 202. Although the stimulation light 203 is emitted only from the emission surface 21a of the first light source 21, it diffuses in the body tissue inside the brain 201. For this reason, the stimulation light 203 propagates inside the brain 201 with a certain degree of spread and reaches the target neuron group 202.

[0051] When the stimulation light is irradiated, the light-gated ion channels of the target neuron group 202 open, and cations flow into the nerve cells. As a result, the nerve cells are enhanced or suppressed, and nerve signals are transmitted (STEP 5). By repeating the irradiation of the stimulation light, synaptic plasticity is expressed in the target neuron group 202. That is, the target neuron group 202 is repaired.

[0052] After the treatment with stimulating light is completed, as shown in Figure 5(b), excitation light is irradiated from the second light source 22 towards the target neuron group 202, and fluorescence emitted from the target neuron group 202 is detected by the image sensor 23 (STEP 6).

[0053] Similar to the stimulating light 203, the excitation light 204 is emitted only from the emission surface 22a of the second light source 22, but it diffuses within the brain 201 and irradiates the target neuron group 202. As a result, fluorescence is generated from the target neuron group 202 over a relatively wide area.

[0054] The image obtained from the fluorescence 205 detected by the image sensor 23 is observed on the display 67 to confirm the degree of repair of the target neuron group 202. In other words, the therapeutic effect is confirmed (STEP 7).

[0055] If the therapeutic effect is deemed insufficient, the stimulating light can be irradiated onto the target neuron group 202 again, for example, and the steps to confirm the therapeutic effect can be repeated multiple times. For example, the frequency and intensity can be changed, and the stimulating light from the first light source 21 can be irradiated onto the target neuron group 202 again. The total treatment time is, for example, several hours.

[0056] Image processing techniques may be used to confirm the therapeutic effect. For example, before irradiating with stimulating light, excitation light is first emitted from the second light source 22, an image is acquired by fluorescence, and the control system stores it in the memory of the circuit 65. This allows for a comparison of the fluorescence images of the target neuron group 202 before and after irradiation with stimulating light. The image comparison may be performed by displaying the image before and after irradiation with stimulating light on the display 67 and visually inspecting it, or the control circuit 65 may use image processing to present the regions where there are differences between these two images.

[0057] As described above, in this embodiment, the optical stimulation device 51 for the treatment of neurodegenerative diseases is equipped with an image sensor 23, which allows the degree of activation of the target neuron group 202 to be confirmed by image immediately after irradiation with stimulating light. In other words, the degree of repair of a specific target neuron group 202, that is, the effect of the treatment, can be confirmed on the spot. Therefore, compared to cases where the effect is confirmed only by behavioral manifestation, it becomes possible to analyze in detail the correlation between the effect of the treatment and the nerve cells that produce the effect. Accordingly, according to this embodiment, research and treatment of effective neurological diseases can be carried out.

[0058] (Second Embodiment) Figure 6 shows the structure of the photostimulation device 52 for the treatment of neurodegenerative diseases according to this embodiment, where (a), (b), and (c) are a side view, a top view, and a front view of the photostimulation device 52 for the treatment of neurodegenerative diseases, respectively. The photostimulation device 52 for the treatment of neurodegenerative diseases according to this embodiment differs from the first embodiment in that the support 11' has a strip shape having a pair of opposing main surfaces 11'a and 11'b.

[0059] The substrate 12 on which the first light source 21, the second light source 22, and the image sensor 23 are mounted is positioned on the main surface 11'a, and at least the main surface 12a is parallel to the longitudinal direction.

[0060] In this embodiment, the transparent protective layer 31 is provided over the entire main surface 11'a, covering the first light source 21, the second light source 22, and the image sensor 23.

[0061] The tip portion 11't of the support 11' is tapered, with the width and thickness decreasing towards the tip in both the thickness direction and the width direction (direction perpendicular to the longitudinal direction).

[0062] According to the optical stimulation device 52 for the treatment of neurodegenerative diseases, the support 11' has a strip shape, which allows the size, particularly in the width direction, to be arbitrarily set. Therefore, by setting the width of the main surface 11'a of the support 11' to be larger, the width direction size of the first light source 21, the second light source 22, and the image sensor 23 can be increased. This allows the stimulation light to be emitted over a wider area, making it possible to treat a wide area in a single procedure.

[0063] (Third Embodiment) Figure 7 shows the structure of the photostimulation device 53 for the treatment of neurodegenerative diseases according to this embodiment, where (a), (b), and (c) are a side view, a top view, and a front view of the photostimulation device 53 for the treatment of neurodegenerative diseases, respectively. The photostimulation device 53 for the treatment of neurodegenerative diseases according to this embodiment differs from the first embodiment in that it comprises additional components.

[0064] Specifically, the optical stimulation device 53 for the treatment of neurodegenerative diseases of this embodiment further comprises an electrode 41 and a heat dissipation device 42.

[0065] The electrode 41 is exposed on the surface of the transparent protective layer 31 and is electrically connected to the control device 60' via the wiring section 12w. The electrode 41 can also be integrated onto the image sensor 23.

[0066] The heat dissipation device 42 is, for example, a Peltier element, which dissipates the heat generated by the first light source 21, the second light source 22, or the image sensor 23 from the upper surface 12a side of the substrate 12 to the lower surface 12b side.

[0067] Figure 8 is a block diagram showing the configuration of the optical stimulation device 103 for the treatment of neurodegenerative diseases according to this embodiment. The optical stimulation device 103 for the treatment of neurodegenerative diseases includes a control device 60'.

[0068] The electrode 41 may be used to electrically stimulate a group of target neurons 202 in the brain. In this case, the control device 60' further includes a voltage / current application circuit 71, which can apply an electrical stimulation signal to the electrode 41 based on a control signal from the control circuit 65.

[0069] Furthermore, the electrode 41 may be used to detect nerve signals generated by the target neuronal group. In this case, the control device 60' further includes a voltage / current detection circuit 72, which can detect changes in the potential of the electrode 41 or changes in the charge of the electrode 41 based on a control signal from the control circuit 65.

[0070] Furthermore, the control device 60' is further equipped with a heat dissipation device control circuit 73, which controls the heat dissipation device 42 based on commands from the control circuit 65.

[0071] The optical stimulation device 103 for the treatment of neurodegenerative diseases can provide electrical stimulation signals to the target neuron group 202 in addition to stimulating light. This broadens the range of treatment methods for neurological diseases. Furthermore, by detecting nerve signals with the electrodes 41, the means of observing the target neuron group 202 increases, enabling appropriate treatment for neurological diseases or research and development of treatment methods.

[0072] Furthermore, the inclusion of the heat dissipation device 42 prevents heat generated by the first light source 21, the second light source 22, or the image sensor 23 from propagating to the nearby target neuron group 202 and preventing the target neuron group 202 from being heated. Therefore, even when the target neuron group 202 is repeatedly irradiated with stimulating light, for example, it is possible to prevent the target neuron group from being heated and the target neuron group from being affected by heat. In other words, factors such as interrupting treatment due to heat effects are suppressed, and the therapeutic effect can be enhanced.

[0073] (Other Embodiments) The optical stimulation device and optical stimulation apparatus for the treatment of neurodegenerative diseases of this disclosure are not limited to the embodiments described above and may be modified in various ways. Furthermore, the optical stimulation device and optical stimulation apparatus for the treatment of neurodegenerative diseases of this disclosure are not limited to the treatment and research of Parkinson's disease, but can be suitably used for the treatment and research of other neurological diseases. For example, they can be used for neurological diseases such as epilepsy, depression, anxiety disorders, Alzheimer's disease, chronic pain, schizophrenia, and dystonia.

[0074] Furthermore, the size of the optical stimulation device for treating neurodegenerative diseases described in the above embodiment, as well as the sizes and specifications of the first light source 21, the second light source 22, and the image sensor 23, are merely examples and are not limited to the numerical values ​​exemplified in the above embodiment.

[0075] The optical stimulation device for the treatment of neurodegenerative diseases, the optical stimulation apparatus for the treatment of neurodegenerative diseases, the control method for the optical stimulation apparatus for the treatment of neurodegenerative diseases, the operation method for the optical stimulation device for the treatment of neurodegenerative diseases, and the treatment method for neurodegenerative diseases described herein can also be described as follows.

[0076] The first configuration of the photostimulation device for treating neurodegenerative diseases comprises a support, a first light source supported by the support on a parallel plane parallel to the longitudinal direction of the support and emitting stimulating light in a direction perpendicular to the longitudinal direction, and an image sensor supported by the support on the parallel plane and receiving light incident from a direction perpendicular to the longitudinal direction.

[0077] According to the first configuration, since the image sensor and the first light source are supported on a surface parallel to the longitudinal direction of the support, the emission surface of the first light source can be made larger compared to when light is emitted from the end face of the support, and stimulating light can be irradiated onto the target neuron group over a wide area. In addition, the activation state of the neuronal group can be detected by the image sensor using fluorescence or the like. Therefore, the effect of treatment with stimulating light can be confirmed.

[0078] In the second configuration of the photostimulation device for treating neurodegenerative diseases, the stimulation light emitted from the first light source is irradiated onto a group of target neurons, and the fluorescence emitted by the target neurons repaired by the stimulation light is detected by the image sensor.

[0079] The third configuration of the optical stimulation device for the treatment of neurodegenerative diseases further comprises a substrate having a support surface parallel to the longitudinal direction in the first configuration, and the image sensor and the first light source may be mounted on the substrate.

[0080] The fourth configuration of the photostimulation device for treating neurodegenerative diseases may further include, in the first configuration, a second light source supported by the support in the parallel plane and emitting excitation light in a direction perpendicular to the longitudinal direction. With this configuration, by including the second light source, the wavelengths of the stimulating light and the excitation light can be made different, allowing the target neuron group to be irradiated with light of wavelengths optimal for treatment and observation, respectively. Thus, efficient treatment and observation can be achieved.

[0081] The fifth configuration of the photostimulation device for treating neurodegenerative diseases is characterized in that, in the fourth configuration, the first light source emits light of a first wavelength, and the second light source emits light of a second wavelength, and the first wavelength and the second wavelength may be different from each other.

[0082] In the sixth configuration of the photostimulation device for treating neurodegenerative diseases, the first wavelength may be within the visible light wavelength band, and the second wavelength may be within the ultraviolet light wavelength band.

[0083] In the photostimulation device for treating neurodegenerative diseases according to the seventh configuration, in the fourth configuration, the image sensor, the first light source, and the second light source are arranged in a direction parallel to the longitudinal direction, and the image sensor may be located between the first light source and the second light source. With this configuration, the arrangement of the first light source, the second light source, and the image sensor in the longitudinal direction reduces the cross-sectional area when inserting the device into the body, thereby reducing the invasive effects.

[0084] The optical stimulation device for treating neurodegenerative diseases according to the eighth configuration, in the first configuration, has a support having a strip shape with a pair of opposing main surfaces, and at least one of the pair of main surfaces may be parallel to the longitudinal direction. With this grid pattern, the strip shape of the support greatly increases the degree of freedom in arranging the first light source, the second light source, and the image sensor.

[0085] In the ninth configuration of the photostimulation device for the treatment of neurodegenerative diseases, in the first configuration, the support has a needle shape, and the needle shape may include a recess having a bottom surface parallel to the longitudinal direction. With this configuration, the invasive effects can be reduced because the support has a needle shape.

[0086] The 10th configuration of the photostimulation device for the treatment of neurodegenerative diseases may, in the first configuration, have the first light source being an LED chip and the image sensor being a CMOS image sensor chip containing a plurality of pixels arranged in two dimensions. With this configuration, the volume of each component can be reduced because the first light source, the second light source, and the image sensor are bare chips, thereby reducing the overall volume of the device and minimizing the invasive effects when the photostimulation device for the treatment of neurodegenerative diseases is inserted into the brain.

[0087] The 11th configuration of the optical stimulation device for treating neurodegenerative diseases may further include, in the first configuration, a transparent protective layer covering the image sensor and the first light source, and electrodes exposed on the surface of the transparent protective layer. With this configuration, by including electrodes, it becomes possible to electrically stimulate a group of target neurons or to acquire electrical signals from the group of target neurons. This broadens the range of treatment methods, increases the amount of information obtained from the group of target neurons, and allows for a more detailed analysis of changes in the group of target neurons.

[0088] The 12th configuration of the photostimulator for the treatment of neurodegenerative diseases comprises the photostimulator for the treatment of neurodegenerative diseases described in the 4th configuration, a first light source drive circuit for driving the first light source, a second light source drive circuit for driving the second light source, an image processing circuit for processing signals received from the image sensor, and a control circuit for controlling the first light source drive circuit, the second light source drive circuit, and the image processing circuit.

[0089] A control method for a photostimulator for the treatment of neurodegenerative diseases according to the 13th configuration is a control method for a photostimulator for the treatment of neurodegenerative diseases according to the 12th configuration, wherein the photostimulator for the treatment of neurodegenerative diseases is inserted into the body such that the parallel plane faces the target neuron group, the control circuit controls the first light source drive circuit to irradiate the target neuron group with the stimulating light from the first light source, controls the second light source drive circuit to irradiate the target neuron group with the excitation light from the second light source, and controls the image processing circuit to receive the fluorescence emitted from the target neuron group with the image sensor and acquire an image of the fluorescence.

[0090] A method for operating a photostimulation device for the treatment of neurodegenerative diseases according to the 14th configuration includes the steps of: inserting the photostimulation device for the treatment of neurodegenerative diseases into the body such that the parallel surface of the photostimulation device for the treatment of neurodegenerative diseases described in the 5th configuration faces the target neuron group; irradiating the target neuron group with the stimulating light from the first light source; and irradiating the target neuron group with the excitation light from the second light source, receiving the fluorescence emitted from the target neuron group with the image sensor, and acquiring an image of the fluorescence.

[0091] The method for treating neurodegenerative diseases according to the 15th configuration includes the steps of: introducing an adeno-transmitting virus vector into a group of target neurons using optogenetics to express photo-activated photoion channels in the group of target neurons; inserting the photostimulation device for treating neurodegenerative diseases described in the 4th configuration into the body such that the parallel surface of the photostimulation device for treating neurodegenerative diseases faces the group of target neurons; irradiating the group of target neurons with the stimulating light from the first light source; and irradiating the group of target neurons with the excitation light from the second light source, receiving the fluorescence emitted from the group of target neurons with the image sensor, and acquiring an image of the fluorescence.

[0092] The optical stimulation device and optical stimulation apparatus for the treatment of neurodegenerative diseases disclosed herein can be suitably used for the treatment and research of neurological diseases using optogenetics.

[0093] 11, 11'...Support, 11c...Cylindrical space, 11d...Recess, 11t, 11't...Tip, 11u...Bottom surface, 12...Substrate, 12m...Main part, 12w...Wiring part, 21...First light source, 22...Second light source, 23...Image sensor, 31...Transparent protective layer, 41...Electrode, 42...Heat dissipation device, 51-53...Optical stimulation device for the treatment of neurodegenerative diseases, 60, 60'...Control device, 61...First light source drive circuit, 62...Second light source drive circuit, 63...Signal processing circuit, 65...Control circuit, 66...Input device, 67...Display, 71...Current application circuit, 72...Current detection circuit, 73...Heat dissipation device control circuit, 101, 103...Optical stimulation device for the treatment of neurodegenerative diseases

Claims

1. A photostimulation device for treating neurodegenerative diseases, comprising: a support; a first light source supported by the support on a parallel plane parallel to the longitudinal direction of the support and emitting stimulating light in a direction perpendicular to the longitudinal direction; and an image sensor supported by the support on the parallel plane and receiving light incident from a direction perpendicular to the longitudinal direction.

2. The optical stimulation device for treating neurodegenerative diseases according to claim 1, wherein the stimulating light emitted from the first light source is irradiated onto a group of target neurons, and the fluorescence emitted by the target neurons repaired by the stimulating light is detected by the image sensor.

3. The optical stimulation device for treating neurodegenerative diseases according to claim 1, further comprising a substrate having a support surface parallel to the longitudinal direction, wherein the image sensor and the first light source are mounted on the substrate.

4. The photostimulation device for treating neurodegenerative diseases according to claim 1, further comprising a second light source supported by the support in the parallel plane and emitting excitation light in a direction perpendicular to the longitudinal direction.

5. The photostimulation device for treating neurodegenerative diseases according to claim 4, wherein the first light source emits light of a first wavelength, the second light source emits light of a second wavelength, and the first wavelength and the second wavelength are different from each other.

6. The photostimulation device for treating neurodegenerative diseases according to claim 5, wherein the first wavelength is within the visible light wavelength band and the second wavelength is within the ultraviolet light wavelength band.

7. The optical stimulation device for treating neurodegenerative diseases according to claim 4, wherein the image sensor, the first light source, and the second light source are arranged in a direction parallel to the longitudinal direction, and the image sensor is located between the first light source and the second light source.

8. The photostimulation device for treating neurodegenerative diseases according to claim 1, wherein the support has a strip shape having a pair of opposing main surfaces, and at least one of the pair of main surfaces is parallel to the longitudinal direction.

9. The photostimulation device for treating neurodegenerative diseases according to claim 1, wherein the support has a needle shape, and the needle shape includes a recess having a bottom surface parallel to the longitudinal direction.

10. The optical stimulation device for treating neurodegenerative diseases according to claim 1, wherein the first light source is an LED chip, and the image sensor is a CMOS image sensor chip including a plurality of pixels arranged in two dimensions.

11. The optical stimulation device for treating neurodegenerative diseases according to claim 1, further comprising a transparent protective layer covering the image sensor and the first light source, and an electrode exposed on the surface of the transparent protective layer.

12. An optical stimulation device for the treatment of neurodegenerative diseases, comprising: an optical stimulation device for the treatment of neurodegenerative diseases according to claim 4; a first light source drive circuit for driving the first light source; a second light source drive circuit for driving the second light source; an image processing circuit for processing signals received from the image sensor; and a control circuit for controlling the first light source drive circuit, the second light source drive circuit, and the image processing circuit.

13. A method for controlling an optical stimulation device for the treatment of neurodegenerative diseases according to claim 12, wherein the optical stimulation device for the treatment of neurodegenerative diseases is inserted into the body such that the parallel planes face a group of target neurons, the control circuit controls the first light source drive circuit to irradiate the group of target neurons with the stimulation light from the first light source, controls the second light source drive circuit to irradiate the group of target neurons with the excitation light from the second light source, and controls the image processing circuit to receive fluorescence emitted from the group of target neurons with the image sensor and acquire an image of the fluorescence.

14. A method for operating a photostimulation device for treating neurodegenerative diseases, comprising the steps of: inserting the photostimulation device for treating neurodegenerative diseases described in claim 5 into the body such that the parallel surface of the photostimulation device for treating neurodegenerative diseases faces a group of target neurons; irradiating the group of target neurons with the stimulating light from the first light source; and irradiating the group of target neurons with the excitation light from the second light source, receiving the fluorescence emitted from the group of target neurons with the image sensor, and acquiring an image of the fluorescence.

15. A method for treating neurodegenerative diseases comprising the steps of: introducing an adeno-transmitting virus vector into a group of target neurons using optogenetics to express photo-activated photoion channels in the group of target neurons; inserting the photostimulation device for treating neurodegenerative diseases described in claim 4 into the body such that the parallel surface of the photostimulation device for treating neurodegenerative diseases faces the group of target neurons; irradiating the group of target neurons with stimulating light from the first light source; and irradiating the group of target neurons with excitation light from the second light source, receiving the fluorescence emitted from the group of target neurons with the image sensor, and acquiring an image of the fluorescence.